Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors

The management of metastatic urothelial cancer is rapidly evolving since immune checkpoint inhibitors were introduced. We present the case of a patient with metastatic upper tract urothelial cancer who had a complete response to durvalumab and tremelimumab. This patient then developed multiple non-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavoie, Jean-Michel, Vandekerkhove, Gillian, Murtha, Andrew J., Wang, Gang, Wyatt, Alexander W., Eigl, Bernhard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254020/
https://www.ncbi.nlm.nih.gov/pubmed/34258232
http://dx.doi.org/10.1016/j.eucr.2021.101762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254020/
https://www.ncbi.nlm.nih.gov/pubmed/34258232
http://dx.doi.org/10.1016/j.eucr.2021.101762

Ejemplares similares